KETCHUM COMMUNICATIONS FORMS HEALTHCARE NETWORK to pull together the resources of Ketchum Advertising, Ketchum Public Relations and its communications unit Botto, Roessner, Horne & Messinger on an as-needed basis. Although the network was not formally in operation, Ketchum has coordinated the three divisions in the past for clients such as Schering-Plough and Ciba Consumer. The network will be under the direction of Robert Botto, who assumes the title of managing director of the new unit in addition to his current post as president and CEO of BRH&M. In a June 7 press release announcing the formation of the network, the agency said Botto will be responsible for "marshaling all the healthcare related resources throughout the Ketchum system." "Recently we've found that our clients' communications needs extend well beyond what most health care advertising agencies currently provide," Botto said. "Consequently, we've found ourselves teaming up with other Ketchum resources in order to resolve our health care clients' marketing issues. As a result, we have formalized the arrangement into a convergent communications capability under the umbrella of the Ketchum Healthcare Network," he explained. The new unit will draw on Ketchum's existing expertise from the agency's various divisions on a client-by-client basis. For each account, a "team" will be formed that will work under the auspices of Ketchum Healthcare Network. Ketchum's current prescription drug clients include Johnson & Johnson (Floxin, Pancrease, Hismanal) and Hoechst-Roussel (Diabeta, Topicort). The OTC roster includes products from SmithKline Beecham, Ciba and Rhone-Poulenc Rorer. New York-based Ketchum Communications, Inc. the corporate entity overseeing Ketchum Advertising, Ketchum Public Relations and BRH&M is listed in the January 1993 Standard Directory of Advertising Agencies as billing approximately $1.03 bil. annually. The firm employs more than 1,000 people.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.
